Peripartum cardiomyopathy
Herz - 2018
Tóm tắt
Peripartum cardiomyopathy (PPCM) is a rare and potentially life-threatening disease that occurs toward the end of pregnancy or in the months following delivery in previously heart-healthy women. The incidence varies widely depending on geographical region and ethnic background, with an estimated number of 1 in 1000–1500 pregnancies in Germany. The course of the disease ranges from mild forms with minor symptoms to severe forms with acute heart failure and cardiogenic shock. The understanding of the etiology of PPCM has evolved in recent years. An oxidative stress-mediated cleaved 16-kDa fragment of the nursing hormone prolactin is thought to damage endothelial cells and cardiomyocytes. Bromocriptine, a dopamine-receptor agonist, effectively blocks prolactin release from the pituitary gland. In addition to standard heart failure therapy, this disease-specific treatment reduces morbidity and mortality in PPCM patients. This review summarizes the current knowledge on PPCM and the disease-specific treatment options.
Từ khóa
Tài liệu tham khảo
Berg CJ, Callaghan WM, Syverson C et al (2010) Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 116:1302–1309
Collaborators GBDMM (2016) Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1775–1812
Nanna M, Stergiopoulos K (2014) Pregnancy complicated by valvular heart disease: an update. J Am Heart Assoc 3:e712
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C et al (2011) ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 32:3147–3197
Sliwa K, Bohm M (2014) Incidence and prevalence of pregnancy-related heart disease. Cardiovasc Res 101:554–560
Hilfiker-Kleiner D, Sliwa K (2014) Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 11:364–370
Bauersachs J, Arrigo M, Hilfiker-Kleiner D et al (2016) Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 18:1096–1105
Haghikia A, Podewski E, Libhaber E et al (2013) Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 108:366-013-0366-0369
Sliwa K, Hilfiker-Kleiner D, Petrie MC et al (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12:767–778
Hilfiker-Kleiner D, Haghikia A, Nonhoff J et al (2015) Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J 36:1090–1097
Ware JS, Li J, Mazaika E et al (2016) Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374:233–241
Pearson GD, Veille JC, Rahimtoola S et al (2000) Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283:1183–1188
Kolte D, Khera S, Aronow WS et al (2014) Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc 3:e1056
McNamara DM, Elkayam U, Alharethi R et al (2015) Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66:905–914
Hilfiker-Kleiner D, Haghikia A, Berliner D et al (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 38:2671–2679
Bello N, Rendon IS, Arany Z (2013) The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 62:1715–1723
Sliwa K, Mebazaa A, Hilfiker-Kleiner D et al (2017) Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail 19:1131–1141
Irizarry OC, Levine LD, Lewey J et al (2017) Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol 2:1256–1260
Bauersachs J (2017) Poor outcomes in poor patients? Peripartum cardiomyopathy-not just black and white. JAMA Cardiol 2:1261–1262
Hilfiker-Kleiner D, Haghikia A, Masuko D et al (2017) Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail 19:1723–1728
Sliwa K, Fett J, Elkayam U (2006) Peripartum cardiomyopathy. Lancet 368:687–693
Mebazaa A, Seronde MF, Gayat E et al (2017) Imbalanced angiogenesis in peripartum cardiomyopathy-diagnostic value of placenta growth factor. Circ J 81:1654–1661
Patten IS, Rana S, Shahul S et al (2012) Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485:333–338
Hilfiker-Kleiner D, Kaminski K, Podewski E et al (2007) A cathepsin D‑cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589–600
Halkein J, Tabruyn SP, Ricke-Hoch M et al (2013) MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123:2143–2154
Levine RJ, Maynard SE, Qian C et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683
Lee YZJ, Judge DP (2017) The role of genetics in peripartum cardiomyopathy. J Cardiovasc Transl Res 10:437–445
Bauersachs J, Koenig T (2018) Devil in disguise: hints and pitfalls in diagnosis of peripartum cardiomyopathy. Circ Heart Fail 11:e4620
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200
Stapel B, Kohlhaas M, Ricke-Hoch M et al (2017) Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J 38:349–361
Labbene I, Arrigo M, Tavares M et al (2017) Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy. Anaesth Crit Care Pain Med 36:39–42
Haghikia A, Tongers J, Berliner D et al (2016) Early ivabradine treatment in patients with acute peripartum cardiomyopathy: subanalysis of the German PPCM registry. Int J Cardiol 216:165–167
Sliwa K, Blauwet L, Tibazarwa K et al (2010) Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121:1465–1473
Arrigo M, Blet A, Mebazaa A (2017) Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J 38:2680–2682
Koenig T, Bauersachs J, Hilfiker-Kleiner D (2018) Bromocriptine for the treatment of peripartum cardiomyopathy. Card Fail Rev 4(1):46–49. https://doi.org/10.15420/cfr.2018:2:2
Duncker D, Haghikia A, Konig T et al (2014) Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16:1331–1336
Duncker D, Westenfeld R, Konrad T et al (2017) Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol 106:582–589
Haghikia A, Rontgen P, Vogel-Claussen J et al (2015) Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. Eur J Heart Fail 2:139–149
Elkayam U (2011) Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 58:659–670
Sliwa K, Petrie MC, Hilfiker-Kleiner D et al (2018) Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1178